Your browser doesn't support javascript.
loading
Volumizing Hyaluronic Acid Filler for Midface Volume Deficit: Results After Repeat Treatment.
Baumann, Leslie; Narins, Rhoda S; Beer, Kenneth; Swift, Arthur; Butterwick, Kimberly J; Few, Julius; Drinkwater, Adrienne; Murphy, Diane K.
Afiliação
  • Baumann L; *Baumann Cosmetic and Research Institute, Miami, Florida; †Dermatology Surgery and Laser Center, New York, New York; ‡Beer Cosmetic, Surgical and General Dermatology, West Palm Beach and Jupiter, Florida; §The Westmount Institute of Plastic Surgery, Montreal, QC, Canada; ‖Cosmetic Laser Dermatology, San Diego, California; ¶Clinical Professor of Surgery, Division of Plastic Surgery, University of Chicago Pritzker School of Medicine, The Few Institute for Aesthetic Plastic Surgery, Chicago, Illino
Dermatol Surg ; 41 Suppl 1: S284-92, 2015 Dec.
Article em En | MEDLINE | ID: mdl-26618455
ABSTRACT

BACKGROUND:

Juvéderm Voluma XC (VYC-20L; hyaluronic acid gel) is approved in the United States for correction of age-related midface volume deficit (MVD).

OBJECTIVE:

Assess safety and effectiveness of VYC-20L after repeat treatment.

METHODS:

Subjects with MVD underwent optional repeat treatment 12 to 24 months after initial treatment if correction was lost or at 24 months regardless of loss of correction (n = 167). Investigators rated outcomes on the Mid-Face Volume Deficit Scale (MFVDS) and the Global Aesthetic Improvement Scale (GAIS). Subject-rated outcomes were the GAIS, overall satisfaction with facial appearance, achievement of treatment goal, and Self-Perception of Age questionnaire. Subjects recorded treatment-site responses in 30-day diaries.

RESULTS:

Mean injection volume for repeat treatment (3.13 mL) was approximately half the mean total injection volume for initial/touch-up treatment (6.8 mL). After repeat treatment, effectiveness was demonstrated on all investigator-rated and subject-rated measures, consistent with results observed after initial treatment. The percentage of subjects improving by ≥1 point on the MFVDS was 82.8% and 91.1% at 6 and 12 months after repeat treatment, respectively. The incidence, severity, and duration of common treatment-site responses were lower after repeat versus initial treatment.

CONCLUSION:

Repeat treatment with VYC-20L was well tolerated and resulted in high levels of effectiveness and subject satisfaction.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article